Key Features of Labcorp's pTau-217/Beta Amyloid 42 Ratioi A first-of-its-kind immunoassay measuring ... or approved by the Food and Drug Administration. This test is not intended as a screening ...

The magnitude of the COVID-19 pandemic has tested the limits of the response capacities of governments, public health and healthcare infrastructure, and diagnostic laboratories. Over the first ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based ...

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria ... 217/Beta Amyloid 42 Ratio i A first-of-its-kind immunoassay measuring two distinct biomarkers known as ...